Internalizing erbB2 antibodies
AssigneeThe Regents of the University of California
InventorsJames D. Marks, Marie Alix Poul
Life of this patent
Estimating the term…
Abstract
This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
Claims12
A method of delivering a chimeric molecule to a cancer cell bearing a c-erbB2receptor, said chimeric molecule comprising an antibody that specifically binds to a c-erbB2epitope, which epitope is bound by F5 (as encoded by ATCC plasmid deposit designation PTA-7843 ) or C1 (SEQ ID NO:
- 2 ) and which antibody is an internalizing antibody, wherein the antibody is coupled to a liposome comprising a therapeutic composition and the chimeric molecule is comprised by a pharmaceutical composition, the method comprising administering the pharmaceutical composition in a dose effective in treating a patient suffering from a c-erbB-2 positive carcinoma.
Dependencies are inferred from the claim text.